This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
This is a prospective, multi-center safety phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of three dose levels of VOY-101 therapy in subjects with late-stage non-neovascular age-related macular degeneration (AMD).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
45
Intravitreal injection of VOY-101
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Retina Consultants of Texas
Bellaire, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Safety Endpoints
1\. Frequency of ocular and systemic adverse events (AEs) (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\])
Time frame: Through 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.